Vaxart, Inc. (NASDAQ:VXRT – Get Free Report) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.83 and traded as low as $0.61. Vaxart shares last traded at $0.70, with a volume of 1,250,310 shares changing hands.
Analyst Ratings Changes
Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.00 target price on shares of Vaxart in a report on Thursday, September 7th.
Vaxart Trading Up 5.1 %
Vaxart (NASDAQ:VXRT – Get Free Report) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. The company had revenue of $1.36 million for the quarter, compared to analyst estimates of $0.10 million. As a group, equities research analysts anticipate that Vaxart, Inc. will post -0.66 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Vaxart
Several large investors have recently modified their holdings of VXRT. Cantor Fitzgerald L. P. bought a new position in shares of Vaxart in the second quarter valued at $5,173,000. State Street Corp lifted its stake in shares of Vaxart by 23.9% in the first quarter. State Street Corp now owns 13,860,974 shares of the biotechnology company’s stock valued at $69,859,000 after buying an additional 2,673,332 shares in the last quarter. Two Sigma Investments LP lifted its stake in shares of Vaxart by 217.1% in the fourth quarter. Two Sigma Investments LP now owns 2,634,716 shares of the biotechnology company’s stock valued at $2,532,000 after buying an additional 1,803,720 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Vaxart by 1,862.7% in the fourth quarter. Millennium Management LLC now owns 1,693,090 shares of the biotechnology company’s stock valued at $1,627,000 after buying an additional 1,606,826 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Vaxart in the fourth quarter valued at $972,000. 19.04% of the stock is currently owned by institutional investors and hedge funds.
Vaxart Company Profile
Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia.
- Five stocks we like better than Vaxart
- How to Invest in EV Charging Stations
- Shocking uranium play that hedge funds kept hidden
- The Dividend Kings With Highest Yield
- Dependable dividends: Why utility stocks are on fire
- 3 Monster Growth Stocks to Buy Now
- Realtor verdict, poor revenue guidance send Zillow stock plunging
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.